Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000216088 | SCV000276109 | uncertain significance | Hereditary cancer-predisposing syndrome | 2016-06-16 | criteria provided, single submitter | clinical testing | The c.5277G>A variant (also known as p.K1759K), located in coding exon 18 of the BRCA1 gene, results from a G to A substitution at nucleotide position 5277. This nucleotide substitution does not change the at codon 1759. However, this change occurs in the last base pair of coding exon 18, which makes it likely to have some effect on normal mRNA splicing. However, one functional study found that this nucleotide substitution is tolerated in a high throughput genome editing haploid cell survival assay (Findlay GM et al. Nature, 2018 10;562:217-222). This nucleotide position is highly conserved in available vertebrate species. Using two different splice site prediction tools, this alteration is predicted by BDGP to abolish the native splice donor site, but is predicted to weaken (but not abolish) the efficiency of the native splice donor site by ESEfinder; however, direct evidence is unavailable |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000112596 | SCV000326236 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Breast Cancer Information Core |
RCV000112596 | SCV000145432 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 1997-11-14 | no assertion criteria provided | clinical testing | |
Brotman Baty Institute, |
RCV000112596 | SCV001242991 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |